In summary, we obtained novel evidence showing that low expression levels of ALDH1A2 are correlated with an early tumor stage and poor prognosis for ovarian cancer patients, and that its expression is negatively regulated by the methylation of ALDH1A2 via DNMT1 or DNMT3B. This evidence concerns the gene DNMT1 and ovarian carcinoma.